Preclinical study demonstrates reduced tumor growth and improved survival in mice using STING mRNA nanoparticles and copper-modified MSA-2, highlighting an amplified immunotherapy strategy.
STING activation is a promising application therapeutic strategy for cancer immunotherapy. In particular, MSA-2 as an oral STING agonist is discovered to have antitumor activity. However, how to improve the antitumor effect of MSA-2 is a very valuable contribution to cancer immunotherapy. Here, we use two strategies to amplify the antitumor effect of MSA-2 by phospholipid nanoparticles delivering STING mRNA and copper-modified MSA-2. We synthesized a new series of ionizable phospholipid nanoparticles and optimized a phospholipid nanoparticle ( 1A P24) for delivering STING mRNA, increasing the expression of STING protein to bind more MSA-2. Second, we synthesized copper-modified MSA-2 (MSA-2-Cu), which induced cell death by Cu 2+ toxicity. Combining 1A P24@STING mRNA and MSA-2-Cu can crucially decrease tumor growth and increase a mouse’s survival. It is a new treatment strategy through amplifying the STING pathway.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: